CN107921125B - 用于治疗与皮脂分泌过多有关的皮肤问题的多肽和抗体 - Google Patents

用于治疗与皮脂分泌过多有关的皮肤问题的多肽和抗体 Download PDF

Info

Publication number
CN107921125B
CN107921125B CN201680039396.8A CN201680039396A CN107921125B CN 107921125 B CN107921125 B CN 107921125B CN 201680039396 A CN201680039396 A CN 201680039396A CN 107921125 B CN107921125 B CN 107921125B
Authority
CN
China
Prior art keywords
seq
amino acid
polypeptide
amino acids
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680039396.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN107921125A (zh
Inventor
昌基兹·塔基比格洛
王玉田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN107921125A publication Critical patent/CN107921125A/zh
Application granted granted Critical
Publication of CN107921125B publication Critical patent/CN107921125B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201680039396.8A 2015-05-29 2016-05-27 用于治疗与皮脂分泌过多有关的皮肤问题的多肽和抗体 Active CN107921125B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562168374P 2015-05-29 2015-05-29
US62/168,374 2015-05-29
PCT/CA2016/050605 WO2016191864A1 (en) 2015-05-29 2016-05-27 Polypeptides and antibodies to treat skin conditions associated with overproduction of sebum

Publications (2)

Publication Number Publication Date
CN107921125A CN107921125A (zh) 2018-04-17
CN107921125B true CN107921125B (zh) 2021-06-08

Family

ID=57439738

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680039396.8A Active CN107921125B (zh) 2015-05-29 2016-05-27 用于治疗与皮脂分泌过多有关的皮肤问题的多肽和抗体

Country Status (7)

Country Link
US (1) US11117939B2 (https=)
EP (1) EP3307317B1 (https=)
JP (1) JP6853239B2 (https=)
KR (1) KR20180012833A (https=)
CN (1) CN107921125B (https=)
HK (1) HK1245664B (https=)
WO (1) WO2016191864A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107325157B (zh) * 2017-08-07 2020-06-26 温州千瑞生物科技有限公司 调节皮脂分泌的肽以及包含其的化妆品
KR102268921B1 (ko) * 2019-12-10 2021-06-23 강원대학교산학협력단 p53을 활성화하는 펩타이드를 포함하는 조성물
KR102084163B1 (ko) * 2019-12-27 2020-05-15 주식회사 인투앱 프로피오니박테리움 아크네스 균으로부터 유래한 지방산 분해 효소에 특이적으로 결합하는 신규한 항체 및 이의 용도
WO2022051831A1 (pt) 2020-09-11 2022-03-17 Chemyunion Ltda. Composição, uso de composição, método cosmético e método para modular a produção de sebo
CN117003829A (zh) * 2023-07-24 2023-11-07 成都凯捷多肽科技有限公司 一种控油多肽化合物、制备方法及其应用
CN120923629A (zh) * 2024-05-08 2025-11-11 浙江大学医学院附属第一医院(浙江省第一医院) 一种阻断脂质合成的多肽在治疗肿瘤及脂质代谢异常疾病中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101426934A (zh) * 2006-04-25 2009-05-06 株式会社资生堂 以斑部位增强基因群为指标的皮肤斑形成预知方法、皮肤斑形成抑制剂的筛选方法
WO2009121176A1 (en) * 2008-03-31 2009-10-08 The University Of British Columbia Insulin-induced gene (insig) peptide compositions and methods for cytoprotection
CN101674730A (zh) * 2007-02-02 2010-03-17 贝勒医学院 用于治疗代谢疾病的组合物和方法
WO2011129399A1 (ja) * 2010-04-15 2011-10-20 花王株式会社 Ｓｒｅｂｐ抑制剤
CN103998027A (zh) * 2011-10-15 2014-08-20 霍夫曼-拉罗奇有限公司 用于治疗癌症的scd1拮抗剂
KR20140145499A (ko) * 2013-06-13 2014-12-23 코스맥스 주식회사 사과 유래 폴리페놀을 함유하는 피지분비 완화 및 여드름 증상 개선용 화장료 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102325789A (zh) * 2009-02-24 2012-01-18 希尔洛有限公司 用于治疗痤疮和其它病症的内脂素治疗药物
JP5353848B2 (ja) * 2010-09-24 2013-11-27 株式会社アドヴィックス 車両用ブレーキ装置
KR101910419B1 (ko) * 2012-02-10 2018-10-23 애경산업(주) 피지생성 억제용 화장료 조성물
JP5947061B2 (ja) * 2012-02-29 2016-07-06 花王株式会社 Ｓｒｅｂｐ１抑制剤

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101426934A (zh) * 2006-04-25 2009-05-06 株式会社资生堂 以斑部位增强基因群为指标的皮肤斑形成预知方法、皮肤斑形成抑制剂的筛选方法
CN101674730A (zh) * 2007-02-02 2010-03-17 贝勒医学院 用于治疗代谢疾病的组合物和方法
WO2009121176A1 (en) * 2008-03-31 2009-10-08 The University Of British Columbia Insulin-induced gene (insig) peptide compositions and methods for cytoprotection
WO2011129399A1 (ja) * 2010-04-15 2011-10-20 花王株式会社 Ｓｒｅｂｐ抑制剤
CN103998027A (zh) * 2011-10-15 2014-08-20 霍夫曼-拉罗奇有限公司 用于治疗癌症的scd1拮抗剂
KR20140145499A (ko) * 2013-06-13 2014-12-23 코스맥스 주식회사 사과 유래 폴리페놀을 함유하는 피지분비 완화 및 여드름 증상 개선용 화장료 조성물

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Hair Growth Defects in Insig-Deficient Mice Caused by Cholesterol Precursor Accumulation and Reversed by Simvastatin;Bret M. Evers等;《J Invest Dermatol》;20100531;第130卷(第5期);1237-1248 *
Proteasomal degradation of ubiquitinated Insig proteins is determined by serine residues flanking ubiquitinated lysines;Joon No Lee等;《PNAS》;20060328;第103卷(第13期);4958-4963 *
Role of NMDA receptor–dependent activation of SREBP1 in excitotoxic and ischemic neuronal injuries;Changiz Taghibiglou等;《Nature Medicine》;20091122;第15卷(第12期);1399-1406 *
Sterol-regulated ubiquitination and degradation of Insig-1 creates a convergent mechanism for feedback control of cholesterol synthesis and uptake;Yi Gong等;《CELL METABOLISM》;20060131;第3卷;15-24 *
固醇调节元件结合蛋白1c对骨骼肌细胞胰岛素受体底物1表达调控的影响;尹雯雯等;《中华糖尿病杂志》;20140228(第2期);106-111 *

Also Published As

Publication number Publication date
JP6853239B2 (ja) 2021-03-31
US20180305419A1 (en) 2018-10-25
US11117939B2 (en) 2021-09-14
KR20180012833A (ko) 2018-02-06
JP2018517767A (ja) 2018-07-05
EP3307317A4 (en) 2019-01-16
WO2016191864A1 (en) 2016-12-08
HK1245664B (en) 2020-06-26
EP3307317A1 (en) 2018-04-18
CN107921125A (zh) 2018-04-17
EP3307317B1 (en) 2019-09-04

Similar Documents

Publication Publication Date Title
CN107921125B (zh) 用于治疗与皮脂分泌过多有关的皮肤问题的多肽和抗体
JP4717349B2 (ja) 細胞の除去又は破壊を必要とする腫瘍及び他の状態の治療に有効なペプチド
AU2002319050B2 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
CA2690267A1 (en) Small cationic antimicrobial peptides
AU2002319050A1 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
AU2002319049A1 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
HK1245664A1 (en) Polypeptides to treat skin conditions associated with overproduction of sebum
CN114099636A (zh) 使用来源于神经丝蛋白的肽治疗需要破坏或移除细胞的病症的方法
CN101389760A (zh) 有效治疗肿瘤或其他需要除去或破坏细胞的病症的肽
CA2448348A1 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
AU2002256587A1 (en) Peptides derived from neural thread proteins and their medical use
CA2439757A1 (en) Methods of using neural thread proteins to treat tumors and other conditions requiring the removal or destruction of cells
EP3717506A1 (en) Chimeric molecule for targeting c-myc in cells
JP2010239971A (ja) 細胞におけるペルオキシソームカタラーゼ機能の促進
JPH11514207A (ja) 組換えｃ１４０リセプター、そのアゴニストおよびアンタゴニスト、並びに該リセプターをコードする核酸
JP2006515168A5 (https=)
US20080306003A1 (en) Novel Compositions and Methods for Promoting, Inhibiting and Detecting Protein Entry Into Cells
HK1110083A (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant